BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 17912007)

  • 1. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
    Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
    Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
    Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
    Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing, but not T cell-activating, capacity.
    Schimek EM; Zwölfer B; Briza P; Jahn-Schmid B; Vogel L; Vieths S; Ebner C; Bohle B
    J Allergy Clin Immunol; 2005 Dec; 116(6):1327-33. PubMed ID: 16337467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoblotting in the diagnosis of cross-reactivity in children allergic to birch.
    Cudowska B; Kaczmarski M; Restani P
    Rocz Akad Med Bialymst; 2005; 50():268-73. PubMed ID: 16358981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
    Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
    Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy.
    Mittag D; Akkerdaas J; Ballmer-Weber BK; Vogel L; Wensing M; Becker WM; Koppelman SJ; Knulst AC; Helbling A; Hefle SL; Van Ree R; Vieths S
    J Allergy Clin Immunol; 2004 Dec; 114(6):1410-7. PubMed ID: 15577846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
    Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
    J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a low immunoglobulin E-binding mutant of the timothy grass pollen major allergen Phl p 5a.
    Wald M; Kahlert H; Weber B; Jankovic M; Keller W; Cromwell O; Nandy A; Fiebig H
    Clin Exp Allergy; 2007 Mar; 37(3):441-50. PubMed ID: 17359394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
    Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
    J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soybean allergy in patients allergic to birch pollen: clinical investigation and molecular characterization of allergens.
    Mittag D; Vieths S; Vogel L; Becker WM; Rihs HP; Helbling A; Wüthrich B; Ballmer-Weber BK
    J Allergy Clin Immunol; 2004 Jan; 113(1):148-54. PubMed ID: 14713921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
    Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
    J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.
    Siebeneicher S; Reuter S; Wangorsch A; Krause M; Foetisch K; Heinz A; Naito S; Reuter A; Taube C; Vieths S; Scheurer S; Toda M
    Allergy; 2015 Dec; 70(12):1559-68. PubMed ID: 26304061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoallergenic mutants of the Timothy grass pollen allergen Phl p 5 generated by proline mutations.
    Wald M; Kahlert H; Reese G; Krontal N; Zafred D; Keller W; Cromwell O; Fiebig H; Nandy A
    Int Arch Allergy Immunol; 2012; 159(2):130-42. PubMed ID: 22653364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
    Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
    J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens.
    Aghayan-Ugurluoglu R; Ball T; Vrtala S; Schweiger C; Kraft D; Valenta R
    J Allergy Clin Immunol; 2000 Apr; 105(4):803-13. PubMed ID: 10756233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.